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1. Abstract 
Background. Hhereditary cystic kidney diseases are a heterogeneous spectrum of 
disorders leading to renal failure. Clinical features and family history can help to distinguish 
the recessive from dominant diseases but the differential diagnosis is difficult due the 
phenotypic overlap. The molecular diagnosis is often the only way to characterize the 
different forms. A conventional molecular screening is suitable for small genes but is 
expensive and time-consuming for large size genes. Next Generation Sequencing (NGS) 
technologies enables massively parallel sequencing of nucleic acid fragments. 
Purpose. The first purpose was to validate a diagnostic algorithm useful to drive the 
genetic screening. The second aim was to validate a NGS protocol of PKHD1 gene.  
Methods. DNAs from 50 patients were submitted to conventional screening of NPHP1, 
NPHP5, UMOD, REN and HNF1B genes. 5 patients with known mutations in PKHD1 were 
submitted to NGS to validate the new method and a not genotyped proband with his 
parents were analyzed for a diagnostic application. 
Results. The conventional molecular screening detected 8 mutations: 1) the novel p.E48K 
of REN in a patient with cystic nephropathy, hyperuricemia, hyperkalemia and anemia; 2) 
p.R489X of NPHP5 in a patient with Senior Loken Syndrome; 3) pR295C of HNF1B in a 
patient with renal failure and diabetes.; 4) the NPHP1 deletion in 3 patients with medullar 
cysts; 5) the HNF1B deletion in a patient with medullar cysts and renal hypoplasia and in a 
diabetic patient with liver disease.  
The NGS of PKHD1 detected all known mutations and two additional variants during the 
validation. The diagnostic NGS analysis identified the patient’s compound heterozygosity 
with a maternal frameshift mutation and a paternal missense mutation besides a not 
transmitted paternal missense mutation. 
Conclusions. The results confirm the validity of our diagnostic algorithm and suggest the 
possibility to introduce this NGS protocol to clinical practice. 
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2. Background 
2.1. Inherited cystic kidney diseases 
Inherited cystic kidney disease is a poorly understood and identified condition and a 
leading genetic cause of established renal failure. The differential diagnosis of this 
diseases appears difficult and is hampered by the variability of clinical manifestations, 
particularly in the early stage of disease and by the genetic heterogeneity. 
While the development of cysts and progressive impairment of renal function are common 
features, other aspects may help in distinguishing different forms: the age of onset, the 
rate of progression of renal disease and a different extra-renal organ involvement (Conti G, 
2009). 
In their studies, Osathanondh and Potter systematically classified renal cystic diseases 
into four distinct types. Potter syndrome type I is referred to as autosomal recessive 
polycystic kidney disease (ARPKD), type II as renal cystic dysplasia, type III as autosomal 
dominant polycystic kidney disease (ADPKD), and type IV occurs when a longstanding 
obstruction in either the kidney or ureter leads to cystic kidneys or hydronephrosis. 
Particularly types II–IV can be part of many syndromes. While this classification still has an 
impact for pathoanatomical descriptions, it is hardly to be reconciled with clinical and 
genetic entities and, consequently, it is more and more being replaced by the genetic 
nomenclature (Bergmann C, 2014). 
The traditional classification divides these disorders in dominant and recessive diseases in 
relation to the type of transmission. The identification of genes and the study of their 
protein products allowed us to shed light on the pathogenic processes underlying the 
formation of cysts (T Watnick, 2003; Scolari F, 2004). 
2.1.1. Nephronophthisis 
Nephronophthisis (NPH) is an autosomal recessive disease characterized by a chronic 
tubulo-interstitial nephritis that progresses to terminal renal failure during the second 
decade in the juvenile form or before the age of 5 years in the infantile form (Hildebrandt F 
et al, 2009). 
This disease is one of the most common causes of end stage renal disease in children 
with an incidence of 10-15%, is the third hereditary pediatric disease leading to dialysis 
and transplantation, and occurs with a prevalence of 1:100,000 individuals (Hildebrandt F 
et al, 2007). 
The normal or slightly reduced  kidney volume, the loss of cortico-medullary differentiation, 
the increased echogenicity and the development of cysts with a diameter ranging from 1 to 
15 mm at the level of the cortico-medullary junction are typical clinical features (Figure 1). 
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Figure 1: Sonographic features of nephronophthisis. Renal ultrasonography shows the presence of cortico-
medullary cysts (Roslyn JS, 2009). 
 
Histologically, tubular basement membrane disintegration and thickening, tubular atrophy, 
and disproportionate tubulointerstitial fibrosis with minimal inflammation are observed 
(Figure 2). 
 
 
Figure 2: a–d Renal histology of a 14-year-old female with juvenile NPH carrying a homozygous NPHP1 
deletion. Chronic tubulo-interstitial alterationswith tubular basement membrane disintegration and thickening, 
focal tubular atrophy (arrow in d), cystic dilated tubuli (asterisk in b and c), and disproportionate tubulo-
interstitial fibrosis with some inflammatory cells were observed (Omran H, 2008). 
 
To date, about 20 genes have been described for recessive NPH, plus XPNPEP3 in which 
mutations cause an NPHlike phenotype (NPHP1L) (Bergamon C, 2014). In Table 1 are 
reported all mutated NPH associated genes. 
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Locus Gene Chromosome Protein Mutation 
frequency  
Extrarenal features 
NPHP1 NPHP1 2q13 Nephrocystin-1 23% SLS, JS, 
NPHP2 INV 9q31 Inversin 1-2% SLS, HF VSD, situs 
inversus 
NPHP3 NPHP3 3q22.1 Nephrocystin-3 <1% SLS, HF, MKS, situs 
inversus 
NPHP4 NPHP4 1p36.22 Nephrocystin-4 or nephroretinin 2-3% SLS 
NPHP5 IQCB1 3q21.1 Nephrocystin-5 or IQ motif containing B1 3-4% SLS 
NPHP6 CEP290 12q21.32 Centrosomal protein 290 1% LCA, SLS, JS, MKS, 
BBS 
NPHP7 GLIS2 16p13.3 GLI similar 2 <0.5% / 
NPHP8 RPGRIP1L 16q12.2 RPGRIP1-like 0.5% SLS, JS, MKS 
NPHP9 NEK8 17q11.1 NIMA-related kinase 8 <0.5% SLS 
NPHP10 SDCCAG8 1q44 Serologically defined colon cancer 
antigen 8 
<0.5% SLS, BBS-like 
NPHP11 TMEM67 8q22.1 Transmembrane protein 67 <0.5% JS, HF, MKS 
NPHP12 TTC21B 2q24.3 Intraflagellar transport protein 139 <1% JS, MKS, BBS, JATD 
NPHP13 WDR19 4p14  WD repeat-containing protein 19 <0.5% retinal microaneurysm 
NPHP14 ZNF423 16q12.1  Zinc finger protein 423 <0.5% JS 
NPHP15 CEP164 11q23.3  Centrosomal protein 164 <0.5% LCA, SLS 
NPHP16 ANKS6 9q22.33  ankyrin repeat and sterile alpha motif 
domain-containing protein 6 
<0.5% / 
NPHP17 IFT172 2p23.3 Intraflagellar transport 172 <0.5% thoracic dysplasia, 
polydactyly 
NPHPL1 XPNPEP3 22q13 X-prolyl aminopeptidase 3 <0.5% cardiomyopathy, 
seizures 
  
Table 1: mutated genes in Nephronophthisis and associated extrarenal manifestations. BBS: Bardet-Biedl 
syndrome; HF: hepatic fibrosis; JATD: Jeune asphyxiating thoracic dystrophy; JS: Joubert syndrome; LCA: 
Leber’s congenital amaurosis; MKS: Meckel-Gruber syndrome; SLS: Senior-Loken syndrome; VSD: 
ventricular septal defect. 
 
Given that these genes only account for about one-half of all NPH cases, further 
heterogeneity can be expected. NPHP1 on chromosome 2q13 is the most commonly 
mutated gene in NPH. In large series of patients, a homozygous deletion of NPHP1 was 
present in 20–40%of cases; heterozygous deletions were found in another 6 % of patients, 
harboring a concomitant point mutation on the other parental NPHP1 allele .  
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Other NPH genes described to date may only contribute a minor part to the total 
mutational load of typical NPH (Salomon et al,  2009). 
It is important to note that many NPH genes are pleiotropic and can cause a much broader 
phenotypic spectrum (with other ciliopathies such as Senior–Loken, Joubert, Meckel, 
Ivemark, and Jeune syndrome) than just isolated NPH. Mutations in a subset of NPH 
genes can resemble PKD with enlarged kidneys and sometimes even prenatal 
manifestation of Potter’s sequence. Obviously, these respective NPHP members engage 
in a closely assembled protein–protein interaction sub-network (Figure 3). 
 
 
Figure 3: Schematic diagram of a primary cilium and associated processes (Bergmann C, 2014) 
 
Positional cloning of these genes and functional characterization of their encoded proteins 
(nephrocystins) has contributed to a unifying theory that defines cystic kidney diseases as 
“ciliopathies”. The theory is based on the finding that all the mutated proteins in cystic 
kidney diseases of humans or animal models are expressed in primary cilia or 
centrosomes of renal epithelial cells. The ciliary theory explains the multiple organ 
involvement in NPHP, which includes retinal degeneration, cerebellar hypoplasia, liver 
fibrosis, situs inversus, and mental retardation. 
2.1.2. Medullary cystic kidney disease 2 and Familial juvenile hiperuricemic    
nephropathy type1 
UMOD-associated kidney disease (uromodulin-associated kidney disease) is also known 
as familial juvenile hyperuricemic nephropathy type 1 (FJHN1) and medullary cystic kidney 
disease type 2 (MCKD2). Clinical findings typically include hyperuricemia and gout 
(resulting from reduced kidney excretion of uric acid) that usually occur as early as the 
teenage years. Slowly progressive interstitial kidney disease begins early in life. Elevations 
in serum creatinine usually occur between ages five and 40 years, leading to end-stage 
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kidney disease (ESRD) usually between the fourth and seventh decade. The age at ESRD 
varies both between and within families (Bleyer AJ, 2013). 
The study of common genomic regions critical, has allowed us to detect the presence of 
mutations within the same gene locus identified as UMOD (Hart T, 2002; Calado J, 2005). 
The UMOD gene is located on chromosome 16 and comprises 11 exons. This gene is 
transcribed only in kidney and encodes for the Uromodulin also known as Tamm-Horsfall 
protein, a glycoprotein of 95-kDa. 
MCKD is often clinically regarded as the autosomal dominant counterpart of NPH (NPHP–
MCKD complex) with a usually later onset of renal failure than the recessive forms. The 
ciliary protein uromodulin (= Tamm– Horsfall glycoprotein), the most abundant protein in 
the urine of healthy individuals, plays a major role and is encoded by UMOD on 
chromosome 16p12 (Vylet’al P et al, 2006). 
Mutations in this gene can lead to different tubulointerstitial nephropathies, including 
MCKD2, glomerulocystic kidney disease, and familial juvenile hyperuricemic nephropathy , 
which may also be caused by mutations in TCF2 (HNF1ß) and REN (renin). Only recently 
has MUC1, a locus mapped more than a decade ago on chromosome 1q22, been 
identified as the gene underlying MCKD1 (Kirby A, 2013). 
Kiser et al. (2004) noted that the diagnosis of MCKD is difficult because initial signs and 
symptoms may be mild or vague, symptoms of frank renal failure occur late, renal cysts 
may be absent in over 50% of patients, and renal histologic abnormalities are nonspecific. 
The MCKD occurs with a prevalence of 1-9/1.000.000 individuals and is mainly 
characterized by alteration of the urine concentration, hyperuricemia, tubulo-interstitial 
fibrosis and progressive renal failure (Scolari F, 2004).  
Frequently observed the presence of renal cysts at the cortico-medullary junction and the 
histology of the renal parenchyma showing tubular atrophy and appearance of a mild 
inflammatory infiltrate (Lhotta K, 2009) (Figure 4). 
 
 
 
Figure 4: renal biopsy of a 27 years patient with chronic renal failure and hypertension (Bisceglia M, 2006). 
 
Two forms of MCKD have been distinguished in relation to the age of chronic renal failure 
onset: MCKD1 and MCKD2 with onset of 62 and 32 years respectively.  
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The clinical features of FJHN1 include hyperuricemia, gout, polyuria, polydipsia, and 
progressive renal failure from the young age. Rarely renal cysts are reported in patients 
with FJHN1 (Izzi C, 2010). 
2.1.3. Familial juvenile hyperuricemic nephropathy type2 
The family juvenile hyperuricemic nephropathy type 2 (FJHN2), described for the first time 
in 1960 by Duncan and Dixon, is an autosomal dominant chronic tubulointerstitial nephritis, 
(Duncan H, 1960). 
FJHN2 is a rare disorder (prevalence < 1/1.000.000) that occurs during childhood and 
progresses to chronic renal failure during the fourth/sixth decade of life. The majority of 
children show anemia, hyperuricemia (serum uric acid > 6 mg / dl), hematuria and reduced 
ability to concentrate urine resulting in the development of polyuria within the first year of 
life (Bleyer AJ, 2010).  
The size of the kidneys is normal or slightly reduced, with no evidence of renal cysts. 
Histological examination reveals focal tubular atrophy, secondary glomerular scarring and 
interstitial fibrosis. FJHN2 is caused by mutations of REN gene, located on chromosome 1 
and made of 10 exons. Most of the known mutations are missense, small deletions, and 
small inframe insertions located in the first and second exon. REN encodes for renin, a 
proteolytic enzyme of 37 Kd produced by the liver as Pro- renin and subsequently 
activated in the juxtaglomerular cells of the kidney. The renin acts by activating the 
conversion of angiotensinogen to angiotensin I. REN mutations result in a reduced 
expression of protein up to the complete loss of nephrons and progressive renal failure 
(Bleyer AJ, 2013). 
 
2.1.4. Renal cysts and diabetes syndrome 
The term of renal cysts and diabetes syndrome (RCAD) has been recently proposed to 
substitute for maturity onset diabetes of the young 5 (MODY5) due to the higher 
prevalence of renal phenotypes than early-onset diabetes. RCAD/MODY5 has been widely 
reported either in the form of case reports or cohort studies, and the spectrum of HNF1B 
anomalies and clinical phenotypes have been substantially changing over the past decade 
(Chen YZ, 2010) 
HNF1B gene consists of nine exons and encodes the 557-amino acid hepatocyte nuclear 
factor 1-beta (HNF1β). It is an atypical Pit-1/Oct-1/Unc-86 (POU) transcription factor 
comprising three distinct domains: an N-terminus dimerization domain, a highly conserved 
DNA binding domain, and a C-terminus transactivation domain.  
In Figure 5 the HNF1β target genes that are implicated in human diseases are listed. The 
genes encoding the transcription factor HNF4A (MODY1) and the protein tyrosine 
phospatase-BL (PTP-BL) affect differentiation and proliferation of beta-cells in the 
pancreas. Dysregulation of both processes are implicated in maturity onset diabetes in the 
young. In contrast, the gene encoding the GPI anchored uromorulin (Umod) as well as the 
genes encoding proteins that are preferentially localized in the primary cilium, i. collectrin 
(Tmem27), kinesin family member 12 (Kif12), polycystin2 (Pkd2), polyductin (Pkhd1), are 
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activated by HNF1β in epithelial cells of the kidney. They are involved in primary cilium 
function and/or epithelial tubulogenesis and dysfunction of both processes lead to 
polycystic kidney disease. In the case of Pkhd1 dysfunction a distorted orientation of the 
mitotic spindle has been reported that leads to renal tubular enlargement and cyst 
formation (Gerhart U R, 2009). 
 
 
 
Figure 5: HNF1B in human diseases.  
 
Mutation in HNF1B was first described by Horkawa et al in 1997. Subsequently, different 
mutation types, such as missense, nonsense, frameshift, splice-site mutations, single exon 
deletion/duplication, and small in-frame deletion, have been increasingly identified in 
different domains.  
Thomas et al first detected HNF1B deletion in 2005, and HNF1B whole-gene deletion may 
be the most common mutational mechanism. 
Mutations are strikingly located within the DNA binding domain and varied among exons of 
the DNA binding domain: exons 2 and 4 are the hottest spots, while mutations are 
sporadically distributed in exon 3. The consistent phenotypes are renal structure 
anomalies (RSA) (89.6%) and diabetes mellitus (DM) (45.0%). However, the concurrence 
of RSA and DM is relatively low (27.5%), which hinders the optimal performance of genetic 
testing and obtainment of timely diagnosis. Other organ involvements are complementary 
and necessary for the early identification of patients with HNF1B anomalies. Analysis of 
phenotypes of HNF1B point mutations shows significant differences in the detection rates 
of RSA, impaired renal function and DM according to mutation type but not mutation 
location. 
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There are so many other features that could provide vital clues to the identity of HNF1B 
anomalies carriers, which include exocrine pancreas dysfunction (6.6%), pancreas 
structural abnormalities (10.4%), asymptomatic liver dysfunction (15.2%), liver structure 
anomalies (4.3%), genital tract malformations (13.7%), and intrauterine growth retardation 
(3.3%) (Chen YZ, 2010). 
2.1.5. Polycystic kidney disease 
Polycystic kidney disease (PKD) includes a subset of hereditary kidney diseases 
characterized by the progressive formation and growth of fluid-filled cysts in both kidneys. 
Based on its mode of inheritance, the PKD is classified as an autosomal dominant and 
autosomal recessive form. In Table 2 are reported clinical and pathophysiological aspects 
of two forms. 
 
Characteristics ARPKD ADPKD 
Synonyms   Potter type I Potter type III 
Incidence Approx.   1:20.000 1:500–1.000 (approx. 2 % early manifesting) 
Pathology of kidneys   
Macroscopy   Massively, symmetrically enlarged kidneys 
(reniform) 
Generally enlarged (also reniform), but usually to 
a lesser extent 
Location of cysts  Dilated collecting ducts and distal tubules  Cysts in all parts of the nephron (including 
glomerulus) 
Ultrasound and diameter 
of cysts 
At onset, typical pepper–salt pattern evident 
on ultrasound scan, increased echogenicity of 
renal parenchyma throughout cortex and 
medulla due to tiny, sometimes invisible cysts 
(usually <2 mm); with advancing age, cysts up 
to several centimeters large appear, similar to 
ADPKD pattern 
Cysts in all parts of the nephron (including 
glomerulus)Cysts of different size in cortex and 
medulla (usually several larger cysts in adults); at 
onset often small, however, sometimes already 
several centimeters early in childhood 
Pathology of liver Mandatory: ductal plate 
malformation/congenital hepatic fibrosis with 
hyperplastic biliary ducts and portal fibrosis 
(may impress as Caroli disease) 
“Liver cysts” common in adults, but rare in 
children. Occasionally, ductal plate 
malformation/congenital hepatic fibrosis 
Associated anomalies Rarely pancreatic cysts and/or fibrosis; single 
case reports with intracranial aneurysms 
Pancreatic cysts and/or cysts in other epithelial 
organs; intracranial aneurysms in approx. 8 %, 
familial clustering 
Main clinical 
manifestations 
Peri-/neonatal period: respiratory distress 
(30–50 %of cases)With prolonged survival, 
renal insufficiency, portal hypertension, and 
other variable co-morbidities 
General onset 3rd–5th decade with arterial 
hypertension, proteinuria, hematuria, and/or renal 
insufficiency; approx. 2 %earlymanifestation in 
childhood (rarely with perinatal respiratory 
distress) 
Risk for siblings 25% 50 % (except for rare cases of spontaneous 
mutation with 
virtually no risk) 
Risk for own children <1 % (unless unaffected parent is related to 
his/her affected partner, or ARPKD is known 
in the unaffected partner’s family) 
50 % (also for patients with a spontaneous 
mutation) 
Manifestation in affected 
family members 
Often similar clinical course in siblings 
(however, in approx.20 % extensive 
intrafamilial variability 
Variable, however, often similar within the same 
family; in the case of early manifestation approx. 
50 % recurrence risk 
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Parental kidneys No alterations Except for cases of spontaneous mutation, 
usually one parent is affected and shows renal 
cysts (be careful when parents are too young for 
definite clinical diagnosis, namely, <30– 40 years) 
Prognosis In perinatal cases with respiratory distress, 
usually poor; for those surviving the neonatal 
period, much better with renal death in 
approx. 15–30 % in childhood/early 
adolescence, often severe complications (e. 
g., esophageal varices) dueto portal 
hypertension; if possible transplantation (often 
combined kidney–liver TX) 
In early manifesting cases, often better than in 
ARPKD. In “adult” cases, chronic renal failure in 
approx. 50 %by age of 60 years; median age of 
ESRD onset (58.1 vs. 79.9 years in PKD1 vs. 
PKD2) 
 
Table 2: Characteristics of autosomal recessive and autosomal dominant polycystic kidney diseases 
 
Autosomal recessive polycystic kidney disease (ARPKD), although less frequent than the 
dominant form, is a common, inherited kidney disease of childhood. ARPKD belongs to the 
family of cilia-related disorders and shows distinct clinical features and genetics. This 
condition occurs with a frequency ranging from 1:6000 to 1:40,000 live births. 
Although the clinical spectrum in ARPKD is much more variable than generally presumed, 
and even only moderately affected elderly people have been described, then majority of 
patients are severely affected and ARPKD is identified late in pregnancy or at birth. 
Affected fetuses display a “Potter” oligohydramnios phenotype with massively enlarged 
kidneys, pulmonary hypoplasia, a characteristic facies, and contracted limbs with club feet. 
Approximately 30–50 % of affected neonates die shortly after birth from respiratory 
insufficiency due to pulmonary hypoplasia and thoracic compression by the excessively 
enlarged kidneys (Adeva M et al, 2006). 
Ultrasound scans typically show bilaterally enlarged hyperechoic kidneys with poor 
corticomedullary differentiation, retained reniform contour, and multiple tiny cysts confined 
to distal tubules and collecting ducts. With advancing clinical course the kidney structure 
might increasingly resemble the pattern observed in ADPKD with renal cysts that vary 
considerably in size and appearance, often also accompanied by some degree of 
interstitial fibrosis (Figure 6), (Avni FE et al, 2002). 
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Figure 6 : Renal ultrasound scans of babies and young children with ARPKD. Symmetrically enlarged 
echogenic kidneys with fusiform dilations of collecting ducts and distal tubules are arranged radially 
throughout the renal parenchyma from medulla to cortex (Bergamon c, 2014) 
 
Arterial  hypertension, often difficult to control despite multi-drug treatment, usually 
develops during the first months of life and affects up to 80 % of children with ARPKD. 
While the early appearance of ARPKD is typically clearly dominated by renal 
manifestations and associated co-morbidities, histological liver involvement is present in 
every ARPKD patient from early embryonic development on, as reflected by the disease 
term “polycystic kidney and hepatic disease 1 (PKHD1).” These obligatory liver changes 
are characterized by defective remodeling of the ductal plate with congenital hepatic 
fibrosis and biliary duct ectasia, defined as ductal plate malformation (DPM) which is also 
a frequent feature in other ciliopathies such as, for example, Bardet–Biedl, Joubert, 
Meckel, and Jeune syndrome.  
To date, PKHD1 is the only known gene for classical ARPKD, but there is compelling 
evidence for locus heterogeneity and phenocopies. Thus, single heterozygous mutations 
and results that are merely based on linkage need to be interpreted with caution. Patients 
with two truncating mutations generally display a severe phenotype with peri- or neonatal 
death, whereas patients surviving the neonatal period usually carry at least one 
hypomorphic (missense) mutation. Due to allelic heterogeneity and a high level of 
missense mutations and private changes, mutation analysis for PKHD1 is still laborious, 
but it has greatly benefited from the availability of new sequencing techniques. 
PKHD1 is a large gene that extends over a genomic segment of almost 500 kb on 
chromosome 6p12. The longest open reading frame comprises 66 exons that encode 
polyductin/fibrocystin, a type I single-pass transmembrane protein of 4,074 amino acids.  
In common with both ADPKD proteins (polycystin-1 and polycystin-2) and most other 
cystoproteins, fibrocystin is localized to primary cilia with the highest concentration in the 
basal body area. This striking pattern of subcellular localization and known interactions 
with, for example, polycystin-2, place fibrocystin at key sites of microtubule organization. In 
line with its proposed role as a ciliary-localized membrane protein, an 18-residue motif in 
the cytoplasmic tail of fibrocystin serves as a ciliary targeting signal. 
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2.2. The molecular diagnosis of inherited cystic kidney disease 
Knowledge of the family history and the clinical picture, the location and morphology of the 
cysts and any possible extra-renal manifestations should help the physician in the 
decision-making process. When an effort is made to classify the wide array of different 
entities with renal cysts, it might be helpful to first distinguish between acquired and 
inherited forms. An accurate molecular diagnosis of cystic kidney disorders is essential to 
both the management of patients with cystic kidneys and the counseling for their families.  
2.2.1. Conventional mutation screening 
The conventional approach to the molecular diagnosis of hereditary cystic kidney diseases 
consists in a cascade analysis of targeted genes in order from the most probably 
associated  with the disease. To do this, is set a diagnostic decisional algorithm that 
guides the screening of mutations to the positive outcome of the genetic test. 
 
Sanger sequencing 
The most widely used method for the detection of point mutations is the Sanger 
sequencing of the coding regions and the splicing sites. This method devised by Sanger in 
1977 is to date the most reliable tool used in genetics laboratories. 
Sanger’s method, which is also referred as dideoxy sequencing or chain termination, is 
based on the use of dideoxynucleotides (ddNTP’s) in addition to the normal nucleotides 
(NTP’s) found in DNA. Dideoxynucleotides are essentially the same as nucleotides except 
they contain a hydrogen group on the 3’ carbon instead of a hydroxyl group (OH). These 
modified nucleotides, when integrated into a sequence, prevent the addition of further 
nucleotides. This occurs because a phosphodiester bond cannot form between the 
dideoxynucleotide and the next incoming nucleotide, and thus the DNA chain is 
terminated. 
The execution of the original method required a very long time, both for the preparation of 
the sample, both for the reading of the results, in addition to employing radioactive 
substances. To date the performance of the analysis have been simplified by the use of 
automated sequencers and software for data analysis. Even if the execution times are  
quite long, the Sanger sequencing is still the most reliable method for diagnostics with a 
sensitivity of 90%. 
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Figure 7: Schematic view of the automated Sanger (chain-termination) method for DNA sequencing. 
 
dHPLC 
The dHPLC (denaturing high performance liquid chromatography), developed in the 
laboratory of Cavalli-Sforza at Stanford University (USA), is a technique of ion-exchange 
liquid chromatography in reverse phase. 
dHPLC uses heteroduplex formation between wild-type and mutated DNA strands to 
identify mutations. Heteroduplex molecules are separated from homoduplex molecules by 
ion-pair, reverse-phase liquid chromatography on a special column matrix with partial heat 
denaturation of the DNA strands (Figure 8).  
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Figure 8: Mutation screening method by dHPLC. Molecular diagnostics (Balogh et al, 2011)  
 
dHPLC is a very useful method for the screening of a large number of samples for 
mutations. It has mainly been used for the analysis of germline mutations in various 
inherited diseases. The sensitivity of the technique dHPLC for point mutations is of 95/97% 
and therefore can be used to analyze DNA fragments of small size, usually between 100 
and 700 base pairs (Sheffield VC, 1993).  
This technique revealing the presence of a mutation or a polymorphism allows us to 
submit to sequence analysis only positive samples, reducing time and costs of molecular 
tests. 
 
MLPA 
MLPA (Multiplex Ligation-dependent Probe Amplification) is a multiplex PCR method 
detecting abnormal copy numbers of genomic DNA sequences. 
The method is based on the use of oligonucleotide probes complementary to specific gene 
sequences. Each probe is constituted by one end, defined sequence hybridization, 
complementary to a target site on the DNA and from one end of the genomic 
oligonucleotide in which the last twenty base pairs are complementary to a universal 
primer M13. One of the probes has a sequence nonspecific of precise length that will allow 
the recognition of the labeled fragments that will be produced, according to their length. 
Such fragments can be subsequently analyzed by capillary electrophoresis. This technique 
has been used for the analysis of HNF1B rearrangements of RCAD affected patients. 
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Figure 9: outline of MLPA technique: After hybridisation to their target sequence in the sample DNA, the 
probe oligonucleotides are enzymatically ligated. One probe oligonucleotide contains a non-hybridising 
stuffer sequence of variable length. Ligation products can be amplified using PCR primer sequences X and Y 
amplification product of each probe has a unique length (130-480 nt). Amplification products are separated 
by electrophoresis.  (Jiufeng S, 2011). 
 
Multiplex PCR for large deletion analysis 
The multiple polymerase chain reaction (Multiplex PCR) is a variant of the conventional 
PCR. Multiplex PCR is a widespread molecular biology technique for amplification of 
multiple targets in a single PCR experiment. In a multiplexing assay, more than one target 
sequence can be amplified by using multiple primer pairs in a reaction mixture (Figure 10) 
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Figure 10: Outline of Multiple PCR method. 
 
As an extension to the practical use of PCR, this technique has the potential to produce 
considerable savings in time and effort within the laboratory without compromising on the 
utility of the experiment. Multiplex PCR is used for the identification of large homozygous 
deletions of NPHP1 gene in patients with clinical suspect of Nephronophthisis; the analysis 
protocol has been validated by Hildebrandt F (1997). 
2.2.2. Next generation sequencing for molecular diagnostics applications 
The introduction of high-throughput techniques (HT) has greatly increased the possibility of 
analysis of biological molecules. The term High-Throughput refers to the simultaneously 
ability to perform numerous measurements. The field of genomics has been the first to 
benefit from the HT technology with the development of so-called high-throughput 
sequencing (HTS), or next generation sequencing (NGS). 
The advent of NGS technology has opened important perspectives in molecular 
diagnostics and represents a powerful tool for the simultaneous analysis of a large number 
of coding regions. The application of this technique in molecular analysis of large genes 
such as PKHD1 would greatly reduce long analysis times. 
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2.2.3. Ion Torrent PGM platform 
The Ion Torrent PGM platform uses a semiconductor technology: the core of the platform 
is a semiconductor chip containing an array with millions of micro-wells as many sensors. 
Each micro-well houses a single sphere containing multiple copies of the same strand of 
ssDNA. This platform works with the “sequencing by synthesis” technology. The 
incorporation of a new nucleotide during synthesis produces the release of two waste 
products: the pyrophosphate (PPi) and hydrogen ions (H +). Every time a single type 
dNTP (dATP, dTTP, dCTP or dGTP) is added to the chip and is incorporated in the 
growing chain, the pH sensitive semiconductor detects the protons increase. The lowering 
of pH generates an increase of the current on the sensitive surface which is converted in a 
variation of potential. After the chip is flooded with a single type of dNTP, the signals are 
recorded; a wash is executed to restore the pH conditions. This step is necessary to detect 
the addition of the next dNTP. The received signals are reported in a Ionogram. The 
workflow of Ion PGM system consists of a few basic steps (Figure 11). 
 
Figure 11: Workflow for sequencing protocol by Ion Torrent PGM 
 
 Library preparation 
During the library preparation the amplicons of 100-400 bp are bound to the adapter 
sequences. 
To do this the target sequences are amplified by PCR and the specific primers are 
submitted to enzymatic digestion. The enzymatic reaction allows the binding of the 
adapters to 5’ or 3’ of digested amplicons. Subsequently the barcodes are linked to 
distinguish different samples. The use of barcodes of 6-10 nucleotides is useful for 
analyzing multiple samples in the same run (Figure 12). 
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Figure 12: Schematic view of library preparation 
 
 Template preparation 
The fragments generated during the library preparation are attached to beads and 
amplified using emulsion PCR (emPCR). Beads coated with complementary primers are 
mixed with a dilute aqueous solution containing the fragments to be sequenced along with 
the necessary PCR reagents (Figure 12). This solution is then mixed with oil to form an 
emulsion of microdroplets. The concentration of beads and fragments is kept low enough 
such that each microdroplet contains only one of each. Clonal amplification of each 
fragment is then performed within the microdroplets. Following amplification the emulsion 
is ‘broken’ (generally by organic extraction and centrifugation) and the amplified beads are 
enriched in a glycerol gradient.  
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Figure 13: Phases of emulsion PCR 
 
 Sequencing 
The first step consists in loading the chip on the Ion Torrent PGM. The balls bound  to the 
template and the polymerase are pushed to uniformly fill the wells of the chip by 
centrifuging. Once the chip is placed on the platform the cycles of washing are alternated 
with cycles of synthesis. The synthesis and the data acquisition are simultaneously 
performed. The Ion Torrent PGM machine is direct connected with the Torrent Suite 
Software and the transmitted data are normalized and converted to the ionogram.  
 
 Data analysis 
The Ion Torrent system generates standard output files like FASTQ that are aligned with 
the reference genome by the Variant Caller. Only reads with high quality score are filtered 
(error rate <1%). The final output is a .bam file format containing all variants information. 
The .bam files can be loaded in all the software for the variants analysis (Figure 14). 
 
Figure 14: Schematic view from acquisition to data analysis. 
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3. Purpose 
The first purpose of this study was to perform a conventional molecular screening of 
inherited cystic kidney diseases in order to validate a diagnostic algorithm related to 
clinical phenotypes improving the genetic screening. This diagnostic algorithm drives the 
identification of the causative variants of NPHP1, NPHP5, UMOD, REN and HNF1B, 
starting from the most likely involved gene.  
Due the size of the PKHD1 gene, the second aim of the project was to develop and 
validate a NGS protocol to enable the mutational screening. The assay is more 
comprehensive, rapid and inexpensive, compared to the conventional method and could 
improve the clinical practice allowing the genetic counseling for families.  
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4. Methods 
4.1. Diagnostics algorithm for patients selection 
A diagnostic algorithm related to the clinical phenotypes has been developed to drive the 
molecular screening. 
The diagnostic flowchart used for the patients selection and for the choice of the genes to 
analyze is an adaptation of the one proposed by Rèmi Salomon et al (2009) (Figure 15). 
 
 
 
Figure 15: Diagnostic algorithm used for patients selection 
 
Patients undergoing genetic screening were selected in the departments of Nephrology 
and Medical Genetics at the S. Orsola-Malpighi Hospital of Bologna, after obtaining 
informed consent for genetic study. Once ultrasound and urinalysis have excluded 
polycystic kidney and glomerulonephritis, the presence of extrarenal manifestations has 
been verified. NPHP5 and HNF1B have been analyzed in patients whom showed Retinitis 
Pigmentosa and diabetes respectively. If the result was negative the clinical phenotype 
25 
 
was re-evaluated in order to go on with the screening of the genes more frequently 
associated with the absence of extrarenal manifestations. NPHP1 analysis was performed 
in patients in whom the onset of kidney disease occurred before the age of 20 years. In 
case of negative result the samples have been submitted to the analysis of REN and 
UMOD in patients with age of onset less than and greater than 20 years respectively. In 
patients with clinical suspicion of ADPKD the analysis of gene PKHD1 was performed 
using the Ion Torrent PGM platform. 
 
4.2. DNA extraction 
The DNA extraction from blood cells was performed by a semi-automatic technique using 
the Maxwell® 16 machine (Promega Corporation, Madison, WI USA). This tool allows to 
perform the automated extraction up to a maximum of 16 samples. Maxwell 16 reduces 
the risk of contamination and allows to standardize the DNA concentration. 
The Maxwell 16 System used a paramagnetic-particle handling system that processes 
samples using Maxwell reagent kits (Figure 16). 
 
 
Figure 16:  Panel A. The Maxwell 16 Instrument. Panel B. A Maxwell 16 reagent cartridge, cut away to 
show the plunger. The design of the cartridge allows direct processing of a sample with no need for 
preprocessing. Panel C. Top view of the Maxwell 16 DNA Purification Cartridge. 
 
The DNA concentration and purity have been measured using a NanoDrop 
spectrophotometer (Figure 17) (Celbio s.p.a., Milan, Italy). Each sample was normalized to 
a concentration of 30-50 ng / L. and stored at -20 ° C. 
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Figure 17: Nanodrop Spectrophotometer 
4.3. Conventional methods for mutation screening 
4.3.1. PCR Primers design 
The reference sequences were downloaded from three different databases and compared 
to each other: UCSC Genome Browser, Ensembl, Gene (ge.ucsc.edu),  
(www.ensembl.org), (www.ncbi.nlm.nih.gov/gene). The PCR primers were designed using 
the Primer3 Software (http://primer3.ut.ee). The presence of self-pairing and the specificity 
of amplification were tested by the use of Oligo Analysis Tool (http://www. operon. com 
/tools /oligo-analysis-tool.aspx) and UCSC In Silico PCR (http:// ge. ucsc. edu/ cgi-bin/ 
hgPcr) respectively. Primers with more than four consecutive inter and intra primers self-
pairings were discarded. The possible presence of SNPs at the site of annealing was 
verified by SNPmasker (http://bioinfo.ebc.ee/snpmasker/). 
The sequences of the primers used in PCR reactions are shown in the following tables 
(Table 3 to 7). 
 
NPHP1 
Primer Sequence 5'->3' Target (bp) Exon 
LHX9_4F 
LHX9_4R 
ATATGGCTCTGCCTTGCTTC 
TTGGGCAAAACACACTCTTG 
515 Exon 4 
LHX9_6F 
LHX9_6R 
ACCCCTAAAAGCCAAGTTGC 
CCTAATAGTGTCTTTGTCTTCACTGC 
180 Exon 6 
NPHP1_20F 
NPHP1_20R 
AATGGCACCCTCCATCCTAC 
AATCGTGGAGGATCCATCTG 
436 Exon 20 
NPHP1_5F 
NPHP1_5R 
CACTCATAGCTGGTCTGTTCTTG 
CAGGTGTACAGGCAGAGTTTTC 
339 Exon 5 
NPHP1_7F 
NPHP1_7R 
TGTTTTTACTGGAGGGTTAGGTG 
CCTAAACCTACTTTGATATCCTTTCC 
236 Exon 7 
 
Table 3: Sequence, target size (bp) and  amplified exons for  NPHP1 and  LHX9.
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 NPHP5 
Primer Sequence 5'->3' Target (bp) Exon 
NPH5_3F 
NPH5_3R 
CATTCTGCCTCTCAAACAAGG 
GAGCTTCCTAAAGGTGTGATGTT 
500 Exon 3 
NPH5_4F 
NPH5_4R 
CCTGAGCAGAATGTCCCTGT 
TGAAGGAAAAGTACAACCAAAACC 
567 Exon 4 
NPH5_5F 
NPH5_5R 
AGCCAAGTGTCTTTTATTTGCTG 
CATAGAGATGATTTTTGGAAGGTTG 
544 Exon 5 
NPH5_6F 
NPH5_6R 
CCTAGTGTATCAACTTGTAGCCCTTA 
TTCAACATGGTTTCATTTCAGTG 
487 Exon 6 
NPH5_7F 
NPH5_7R 
GATGGTCATGCTTTGATTTGG 
CAATGGTGATGGAACTTCAGC 
397 Exon 7 
NPH5_8F 
NPH5_8R 
GCACCTTGCACACAGTAGGA 
TCAGAAAAGTATCTTCCACATGC 
598 Exon 8 
NPH5_9F 
NPH5_9R 
TTTTCATTTGTTTTTAAGCCAGA 
TTTTGGGGGTATTTTGCTTG 
340 Exon 9 
NPH5_10F 
NPH5_10R 
TTGCCTTACCAAGCCTAACA 
GATTCCTGTCTTACATCCTTTGC 
477 Exon 10 
NPH5_11F 
NPH5_11R 
CACAACAGCAGCAGATGACA 
AAAAACTGGTGGGGAGATTG 
523 Exon 11 
NPH5_12F 
NPH5_12R 
GCTGCATAATCTGGGAAAGC 
AAAACTAAGGCTCAAGAAAACTAAGTG 
464 Exon 12 
NPH5_13F 
NPH5_13N 
CCTGCATTTTGTCACAGTCC 
ACTTCTATGGTAAAGCCAATGC 
382 Exon 13 
NPH5_14F 
NPH5_14R 
TGATAAAATGAGAGACAGCTAAGCA 
TTCCTGAGGTTAGGGGATGA 
384 Exon 14 
NPH5_15AF 
NPH5_15AR 
TCCAGCTTAGGCAATAGAGCA 
TGTGTGGCTAACGATGAGGA 
597 Exon 15 
 
Table 4: Sequence, target size (bp) and  amplified exons for  NPHP5 .
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 UMOD 
 Primer Sequence 5'->3' Target (bp) Exon 
UM1F 
UM1R 
TGCTGTTAGAAGGTGCGAAA 
CCCCAGTGTCCAAGGTCTTA 
384 Exon 1 
UM2F 
UM2R 
AGACTGGGATGTTGGTGAGG 
GACAGGTGCTACATTGCTTCC 
473 Exon 2 
UM3AF 
UM3AR 
GAATGAGGGAAGGATCTCTGG 
GGCATACGCACAAGTAGCTG 
398 Exon 3 
UM3BF 
UM3BR 
TCCTTCTCCTGCGTCTGC 
CGTGCCATTGAGCCACAT 
438 Exon 3 
UM3CF 
UM3CR 
AGTACGGGGAGGGCTACG 
TCACAGGGACAGACAGACAATC 
400 Exon 3 
UM4F 
UM4R 
GAGTCTCCCCACAGTCCTCA 
ATATGGCCCCAATCTCACAG 
296 Exon 4 
UM5F 
UM5R 
AGCACTTCCAGATGGTGGTC 
TCCTCTCAATACACCTGTGGAG 
490 Exon 5 
UM6F 
UM6R 
GACCAGCAGATTTAGCTTTGAA 
GGTTAAGGGGTTTGGGGTTA 
299 Exon 6 
UM7F 
UM7R 
GGAATGCAAATCAGAGAAGG 
TTTCCTCCATCCAAGTCCAA 
397 Exon 7 
UM8F 
UM8R 
GCTGAAAGGTGACAGAGCAA 
AAGAGGGAAACAGGGAAGAAA 
351 Exon 8 
UM9F 
UM9R 
CATCTATCTAACAAATGGCAGAGC 
CCACTTGCTCCCAGTTCTTC 
379 Exon 9 
UM10F 
UM10R 
CTTGCTAAGGGTTGGGACCT 
CCTTTGGGTTTGTAATAAGTTTGTG 
499 Exon 10 
UM11F 
UM11R 
TAGGAGAGCAGCCCAGAGAG 
ACACCGTCACAAGTCCCATT 
391 Exon 11 
 
Table 5: Sequence, target size (bp) and  amplified exons for UMOD. 
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 REN 
 Primer Sequence 5'->3' Target (bp) Exon 
RENPF 
RENPR 
ACAGGGCCAAGCCAGATAG 
GTCGGGAGACCAAAGGTACA 
373 Promoter 
REN1F 
REN1R 
GGGTAATAAATCAGGGCAGAGC 
ATGTGGAAAAGCCAGGGTGT 
300 Exon 1 
REN2F 
REN2R 
AGCGACAGAGGTGATTTCCA 
GCCTTCGTCAAACACAGCTT 
399 Exon 2 
REN3F 
REN3R 
AAGAGTGAAGCCAGGCAAGA 
GTGTTGGGCAGGATTGCTC 
272 Exon 3 
REN4F 
REN4R 
AACCAGCCATACCCACAATG 
TTGCTCCCCCATAGGTACTG 
393 Exon 4 
REN5F 
REN5R 
GAAGCCCAGACCAGACTCC 
AGATATTGATTGGCTGTCACCT 
391 Exon 5 
REN6F 
REN6R 
CAGTCCCCCACTTGTTCACT 
GGGCTTGCTGATGTGAGTTT 
290 Exon 6 
REN7F 
REN7R 
CACCCTTGTGCAACCTTCC 
GGCAGGATGGTAATGCAGTC 
296 Exon 7 
REN8F 
REN8R 
CCCACACTCAGGAAGGACAT 
TGAGGTGAACAAGCGAAGG 
344 Exon 8 
REN9F 
REN9R 
TCGCTTGTTCACCTCACACT 
GAATCACCTGGGGAAACTGA 
491 Exon 9 
REN10F 
REN10R 
GTGTGGCTAGGGGAGAGATG 
TTGTCCTCAAAGCAGGGAAG 
460 Exon 10 
 
Table 6: Sequence, target size (bp) and  amplified exons for REN  
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 HNF1B 
 Primer Sequence 5'->3' Target (bp) Exon 
MOD5PF 
MOD5PR 
CCCCAGCGTGAGTACAATG 
GGATGGCAGCAACTCCTC 
479 Promoter 
MOD51F 
MOD51R 
ATTTGGGGTTTGCTTGTGAA 
GACTTCTCTGGTGGGAAACG 
547 Exon 1 
MOD52F 
MOD52R 
GCACCCCCTAGAAAAAGAATG 
ATCTGCCAAGTGCTCACAAG 
387 Exon 2 
   MOD53F 
MOD53R 
TGTCTGTCTGCTGAGTGAAGG 
AGGGTTCCTGGGTCTGTGTA 
412 Exon 3 
MOD54F 
MOD54R 
CCAACCAAGACTGCTGTGATT 
CAGATAAGATCCGTGGCAAGA 
400 Exon 4 
MOD55F 
MOD55R 
ACAAGAGGTGCCGAGTCATT 
TCTGGACAGCCCTCATTTTC 
367 Exon 5 
MOD56F 
MOD56R 
CACATCGTGTTGGAAACTGC 
TGGATTTAAGGAGACAGATGAGAA 
364 Exon 6 
MOD57F 
MOD57R 
TTTAATGCCCATCTCCAACC 
CGAGAAAGTTCAGACCCAGAG 
498 Exon 7 
MOD58F 
MOD58R 
AGGAGATGGGAGCTATGGTG 
AACAACAGGGAGCCTCAGAA 
337 Exon 8 
MOD59F 
MOD59R 
GCTGCTCTTTGCTGGTTGAG 
TGAGAGTGGATTGTCTGAGGTG 
299 Exon 9 
 
Table 7: Sequence, target size (bp) and  amplified exons for HNF1B 
 
4.3.2. Deletion analysis of NPHP1 gene 
For the NPHP1 analysis the investigation of three large homozygous deletions was 
performed: NPHP1 exon 5 (339 bp), NPHP1 exon 7 (236 bp), and NPHP1 exon 20 (436 
bp) (Figure 18). 
 
 
 
 
 
Figure 18: Schematic view of NPHP1 and its location on chromosome 2 
Exon 5 Exon 7 Exon 20 
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Each DNA sample was analyzed by multiplex PCR in order to amplify in the same 
reaction, the three regions potentially delete and two control sequences of the gene LHX9: 
exon 4 (515bp) and exon 6 (180bp) (Figure 19).  
 
  
 
Figure 19:  Picture of 5 not deleted controls on agarose gel 
 
The PCR was carried out using the AmpliTaq-Gold Polymerase and reagents kit on the  
GeneAmp PCR system 9700 thermal cycler (Applied Byosystem). The conditions and the 
program for PCR amplification are reported below (Figure 20). 
 
Primer Gene-Exon Oligo Mix % 
LHX9_4F LHX9 Exon4 12.5 
LHX9_4R LHX9 Exon4 12.5 
LHX9_6F LHX9 Exon6 8.33 
LHX9_6R LHX9 Exon6 8.33 
NPHP1_20F NPHP1 Exon 20 8.33 
NPHP1_20R NPHP1 Exon 20 8.33 
NPHP1_5F NPHP1 Exon 5 8.33 
NPHP1_5R NPHP1 Exon 5 8.33 
NPHP1_7F NPHP1 Exon 7 12.5 
NPHP1_7R NPHP1 Exon 7 12.5 
 
Figure 20: Percentage of oligo within the amplification mix and program of amplification 
 
The PCR products were checked by electrophoresis on 2% agarose gel and compared 
with two different molecular weight markers (DNA Molecular Weight, Markers VI-VIII, 
Roche Diagnostics GmbH). 
Temperature Time Number of 
cycles 
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4.3.3. NPHP5 analysis 
For the analysis of NPHP5 the DNA samples were subjected to direct sequencing of the 
coding and flanking regions (Figure 21). 
 
 
Figure 21: Schematic view of NPHP5 and its location on chromosome 3 
 
PCR were performed using the AmpliTaq Gold DNA Polymerase and reagents kit on the 
GeneAmp PCR System 9700 thermal cycler (Applied Byosystem) respecting the 
conditions of amplification of Table 8. 
 
Exon 
Annealing 
Temperature 
(°C) 
Touch-
Down 
3-4-5-6-7-
8-10-11-
12-13-14-
15 
62 No 
9 62-57 
-0.5 °C 
X 10 
cycles 
 
 
Table 8:  PCR conditions and program of amplification for NPHP5 analysis 
 
The PCR products were evaluated by electrophoresis on 2% agarose gel and compared 
with two markers of molecular weight. Subsequently, the amplified DNA was purified using 
the QIA quick PCR Purification Kit (250) (QIAGEN Inc.Valencia, CA) The concentration of 
the purified DNA fragments was assessed by electrophoresis on 2% agarose gel. 
Temperature Time Number 
of cycles 
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The PCR for sequencing were performed using the BigDye Terminator v1.1 Cycle 
Sequencing kit (ABI) on the GeneAmp PCR system 9700 thermal cycler.  
PCR products were purified using the Millipore kit plate and loaded on the automatic 
sequencer 3730 DNA Analyzer, Applied Byosistem (48 capillaries). The results were 
aligned and compared with a reference sequence by using the Sequencer program (Gene 
Codes Corp, Ann Arbor, MI). 
4.3.4. dHPLC analysis and Sanger sequencing of UMOD, REN and HNF1B 
genes  
The poorly polymorphic fragments of UMOD (Figure 22), REN (Figure 23) and HNF1B 
(Figure 24) were submitted to the screening of heteroduplex by dHplc. Remaining 
fragments were submitted to direct sequencing (Table 9). 
 
 
 
 
Figure 22: Schematic view of UMOD and its location on chromosome 16. 
 
 
 
 
Figure 23: Schematic view of REN and its location on chromosome 1. 
 
 
34 
 
 
 
Figure 24: Schematic view of HNF1B  and its location on chromosome 17. 
 
Gene dHPLC Direct sequencing 
UMOD Exons 1-2-6-7-8-9-10-11 Exons 3- 4- 5 
REN Promoter + Exons 1-2-3-4-5-6-7-8-9-10  / 
HNF1B Exons 2-3-4-5-6-7-8-9 Promoter+ Exon 1 
 
Table 9:  fragments of UMOD, REN and HNF1B  analyzed by dHPLC and direct sequencing. 
 
PCR were performed using the AmpliTaq Gold Polymerase and reagents kit on the 
GeneAmp PCR System 9700 thermal cycler (Applied Byosystem) respecting the 
conditions of amplification reported in the following tables (Table 10, Table 11 and Table 
12). 
 
UMOD 
 
Fragment 
Annealing Temperature  
(°C) 
Touch-Down 
Exons 1-2-4-5-6-7-8-10-
11 
62 No 
Exon 3 62-57 
-0.5 °C 
X 10 cicli 
 
Table 10:  Annealing temperatures set up  for PCR amplification of gene fragments of UMOD. 
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REN 
 
Fragment 
Annealing Temperature 
(°C) 
Touch-Down 
Promoter-Exons 1-2-3- 
4-5-6-8-10 
62 No 
Exons 7-9 63-58 
-0.5 °C 
X 10 cicli 
 
Table 11:  Annealing temperatures set up  for PCR amplification of gene fragments of REN. 
 
HNF1B 
 
Fragment 
 Annealing Temperature 
(°C) 
Exon 1 60 
Exons 2-3-4-5-6-7-8-9 62 
 
Table 12:  Annealing temperatures set up  for PCR amplification of gene fragments of HNF1B. 
 
The PCR products were evaluated by electrophoresis on 2% agarose gel and compared 
with two markers of molecular weight.  
The amplified samples to analyze by dHPLC were denatured for 10 minutes at 95°C and 
partially renatured for 10 minutes at room tenperature. The optimal temperatures for 
dHPLC analysis were set up using the Wave Marker dHPLC software. The partially 
denaturing temperatures for each gene are reported in the following tables (Table 13, 
Table 14, Table 15). 
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UMOD 
 
Fragment T1 (°C) T2 (°C) T3 (°C) T4 (°C) 
Exon 1 57.7 58.2   
Exon 2 57.8 58.9 60.3  
Exon 6 60.9 61.7   
Exon 7 58.6 61.5 62.4 63.3 
Exon 8 56.1 59.0 60.2  
Exon 9 60.4 60.9 62.2  
Exon 10 57.3 58.6 59.7  
Exon 11 58.5 59.7 61.6 63.0 
 
Table 13:  Partially denaturating temperatures for dHPLC  analysis of UMOD  
 
REN 
 
Fragment T1 (°C) T2 (°C) T3 (°C) T4 (°C) 
Promoter 61 61,4 - - 
Exon 1 59,4 61,6 62,3 - 
Exon 2 59,5 60,3 61 62,4 
Exon 3 62,2 62,7 - - 
Exon 4 61,6 63,8 
(+0,5) 
- - 
Exon 5 61 62,2 - - 
Exon 6 61,1 61,6 - - 
Exon 7 59,9 60,7 61,1  
Exon 8 61,8 62,4 - - 
Exon 9 58,8 61,9 63,1 
(+0,5) 
- 
Exon 10 60,8 62,5 63,3 
(+0,3) 
- 
 
Table 14:  Partially denaturating temperatures for dHPLC  analysis of REN. 
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HNF1B  
 
Fragment T1 (°C) T2 (°C) T3 (°C) T4 (°C) 
Exon 2 59.2 61.1 62.3  
Exon 3 57.5 59.0 61.3 63.0 
Exon 4 62.1 62.9   
Exon 5 58.5 59.8 60.7 61.9 
Exon 6 56.8 57.7 58.6 59.8 
Exon 7 58.6 61.2 62.4 64.1 
Exon 8 60.9 61.9   
Exon 9 60.0 61.5 62.4 63.7 
 
Table 15:  Partially denaturating temperatures for dHPLC  analysis of HNF1B. 
 
Positive samples by dHPLC were submitted to sequence analysis.  
The PCR products to be sequenced were purified using the QIA quick PCR Purification Kit 
(250) (QIAGEN Inc.Valencia, CA) The concentration of the purified DNA fragments was 
assessed by electrophoresis on 2% agarose gel. 
The PCR for sequencing were performed using the BigDye Terminator v1.1 Cycle 
Sequencing kit (ABI) on the GeneAmp PCR system 9700 thermal cycler.  
PCR products were purified using the Millipore kit plate and loaded on the automatic 
sequencer 3730 DNA Analyzer, Applied Byosistem (48 capillaries). The results were 
aligned and compared with a reference sequence by using the Sequencer program (Gene 
Codes Corp, Ann Arbor, MI). 
 
4.3.5. MLPA analysis of HNF1B gene 
The analysis of deletions/duplications of HNF1B, was performed using the MLPA P241-D1 
MODY kit (MRC-Holland). The P241-D2 MODY probemix contains probes for GCK, 
HNF1A, HNF1B and HNF4A genes and is therefore specific for MODY 1, 2, 3 and 5. Four 
healthy controls were included for each session of analysis. The protocol is divided into 
five phases: 1)Denaturation, 2) Hybridization, 3) Ligation, 4) Amplification, 5) Separation 
and data analysis. 
1) Denaturation 
All DNA samples were normalized in MilliQ water to a concentration of 20 ng /µL, 
transferred within Tube-Strip and denatured at the temperature of 98 ° C for 10 minutes on 
the Gradient Master Cycler 5331 (Eppendorf).  
 
 
38 
 
2) Hybridization 
3 μl of Hybridization Mix were added to each sample. The Hybridization Mix was prepared 
with 1,5 μl of Salsa Probe Mix and 1.5 μl of MLPA Buffer for each sample. The reaction 
was carried out on the thermal cycler at 95 °C for 1 minute and at 60 °C over night. 
3) Ligation 
32 μl of Ligase Mix were aliquoted to each sample. For each sample the mix was prepared 
using 3 μl of MilliQ water, 3 μl of Buffer A, 3 μl of Buffer B and 1 μl of 65 Ligase. The phase 
of the ligation was carried out at the temperature of 54°C for 15 minutes and at the 
temperature of 98°C for 5 minutes. 
4) Amplification 
10 μl of  PCR mix prepared by aliquoting 2 μl of SALSA PCR primers and 0.5 μl of SALSA 
Polymerase were transferred within each Tube-Strip. 
PCR reaction was carried out under the following amplifications conditions (Table 16 )  
 
Temperature 
(°C) 
Time 
(s; m) 
Number of cycles 
95 30 s X 35 
60 30 s 
72 1 m 
72 20 m  
10 ∞  
 
Table 16: Temperature of amplification, time and number of cycles. 
 
5) Separation and data analysis 
The MLPA products were subjected to capillary electrophoresis by the use of the Applied 
Byosistem 3730 DNA Analyzer sequencer. Comparative analysis of samples was 
performed by Coffalyser.NET. 
 
4.4. Next Generation Sequencing  of PKHD1 gene 
4.4.1. Patients selection 
A total of 8 patients were submitted to the molecular screening using the Ion Torrent PGM 
sequencer. For the validation of the NGS methodology, were included 5 subjects 
belonging to 4 different families and carrying known mutations in PKHD1. These samples 
were recruited by the Medical Genetics Unit at the S. Orsola-Malpighi University Hospital 
of Bologna. 
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Subsequently, an affected proband and his unaffected parents were analyzed. This family 
was recruited by the Nephrology, Dialysis and Renal Transplant Unit at the S. Orsola-
Malpighi University Hospital of Bologna. 
 
4.4.2. Assay Design 
The primers design for mutational screening of PKHD1 gene was performed by the use of 
Ion AmpliSeq ™ Designer. This software allows to design a pool of primers suitable for 
multiplex PCR. Each primer is synthesized with a 5’ modification to allow the partial 
digestion during the libraries preparation. The software also provide as output the 
coverage percentage, the DNA concentration for each pool, the length of amplicons and 
the number of bp to be sequenced. A total of 122 partially overlapping amplicons was 
provided. The primers were divided into two pools for the construction of two multiplex 
PCR for sample. A genomic region of 12,245kb corresponding to 99,88% was covered. 
Only a little region of 15 bp near the 5’ of exon 65 was not covered by this design. To 
amplify this region a couple of primers for conventional sequencing was designed (Table 
17). 
 
Amplicon  Pimer Forward Primer Reverse  
PKHD1 ex 65 TTGAACACCTACTATATCCCAGATACT  TTGGGGAAAGAAACAGAATCA  
 
Table 17: Primers used to amplify the 5’ not covered region of the exon 65. 
  
The result of the design can be viewed directly on the UCSC Genome Browser (Figure 25) 
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Figure 25: UCSC Genome Browser. PKHD1 gene is shown in blue, the input sequences are light blue, the 
output targets are green and missed amplicons are red. 
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The designed primers are reported in the Table 18. 
Amplicon ID  Primer Forward Primer Reverse Start End  Pool  
AMPL757196938  TTCTCAAGGTAACCTAT
TGTGTTCTTAC  
TGCTCCAATCAAAACTG
AAAATGCTTTT  
51949621 51949801 2 
AMPL556530457  CTCATAGTCTTTAGGAT
TGTGGGTCAA  
TGCAGAAGGTAGTGGT
TTGAATCTG  
51947911 51948115 1 
AMPL574400093  CTCATCCTGTCTGGTCT
TCCTATTC  
TCTATGCAGCCTGAGAT
TTCTTTCC  
51947151 51947375 2 
AMPL575306224  AACACAAGCACACCCTT
AGACTATG  
GCTAGCTTTGGGAATTC
ATGGTTTT  
51944641 51944864 1 
AMPL574899571  CCACTCACCTAGGTTTG
CAACA  
GTAATGCTGTCTGAGG
AAAGGCTT  
51940999 51941218 2 
AMPL585346281  GTACTCAGCATCAAAAT
CAAAAGTTTCCA  
ATGACCTGCTTTGCCAT
ATTGAGTATA  
51938269 51938450 1 
AMPL575354245  CCAGCTCATGAGGGAC
CATAA  
TGTATATGGCTGGATTA
TCACTGGAAGAT  
51938113 51938326 2 
AMPL571859638  AGAATGTGTGTGTGTTG
TATCCATGT  
AGTTTTGTGAGGAATGT
TTATTGGGAGTA  
51936840 51937064 1 
AMPL574803786  CTTGCAATTGCTTTTGT
CCGGAT  
GCTTTCTACTTTCCTGG
TTAAAGAGTCA  
51935729 51935952 2 
AMPL576093592  AGAAAGTAAGCAAGATG
AGAGAGATAGGT  
GATGATATTGGAGTCTT
TGGGCTTATGA  
51935127 51935338 1 
AMPL573679894  CCAACATTGAGTGAGGC
ACAA  
CTTTCAGGCAGCCGAC
TAAAAA  
51934202 51934402 2 
AMPL584987583  GTAACCTGGGCAGAATT
GTCAAAA  
AGGTCATATTCTGGTCT
ATATTTGGAAGCT  
51930782 51930933 1 
AMPL573053414  CAAAATCCCACCTGGTC
TCAAC  
AGAACAAACATCACAAT
TACAGGAGACTT  
51930613 51930834 2 
AMPL585449128  CCTGGTGGCTTCCTTAC
CT  
TGTATACCTACACACAC
ACACATACAT  
51929736 51929897 1 
AMPL585434545  AAGCCAGTCAAATAGAT
GAGAAAGAAT  
GGAAAAGATGTGAGGC
TCACCA  
51929643 51929786 2 
AMPL575263979  CTTTTGATGTGGGCTCC
CACT  
CGCCCTGTAATGTTTAT
GCGATCT  
51927281 51927495 1 
AMPL575226474  ATGGGTATGGGACTGG
CAAC  
GTTCAGTGATTCAGGC
CTTGGTTA  
51924674 51924895 2 
AMPL574783531  GCTATCCCATGATGCTC
TGCT  
GATGCCTGGAAGCTGC
ATAGTATT  
51923248 51923450 1 
AMPL556230311  GCTCCATGGGACTGGA TGGAGCCATGTACTAC 51923092 51923289 2 
42 
 
AAGAG  CTGGA  
AMPL575433627  GCATAAAGACCACCCCC
AGTT  
TGTGTTCTTAGATTGTC
TCTCTGGCTTA  
51921627 51921847 1 
AMPL573311044  AATCAGAATGAAGCCAC
GGACA  
CCATCTGGTGGGAGAC
TTCTTC  
51921470 51921694 2 
AMPL572981916  CCTACCCACCTGACCCA
GAA  
GCCTGCCTTTCTATTTT
ATCTGAACTG  
51920345 51920561 1 
AMPL574047440  CCTCCCAGCTGACTGAA
TTCC  
GACTGCTTCTTGCACTA
ATAGAACTGA  
51918788 51919012 2 
AMPL573589382  ACCTGTTACGTTTGTGT
CTGCAA  
CAGTTCTGCTCCATGCT
GTTTTTC  
51917872 51918075 1 
AMPL585249067  AAAGGAGGATCACCTGT
TCTCT  
GGGCCTGTTCTATGTG
GATGAAATTATTA  
51917764 51917923 2 
AMPL574989935  GCGAGCCGTTCCAGAAT
CAG  
TGTGTACTGAGATCTGA
GTAACTCACAT  
51915065 51915196 1 
AMPL574964807  CCTCAAGGCCAACAAGC
ATT  
GGATCACTGGTCTCTA
GTTTCTCAAG  
51914896 51915110 2 
AMPL574204858  GTGAGTGAGAATATGTG
AGTGAGAATTGT  
CCCCAACCCAGACGTT
AATACT  
51913238 51913459 1 
AMPL572624939  AAGGTCCACACGTGTTC
GTAG  
TGAGGATGAAACTCTGT
AAGGTGGATTA  
51910845 51911055 2 
 
Table 18: AmpliSeq Ion Designer output. The Amplicons ID, the sequences of forward and reverse primers, 
the chromosome position of the start and the end and the reference primers pool are reported. 
4.4.3. DNA Libraries construction. 
The DNA libraries were constructed using the Ion AmpliSeqTM Library Kit 2.0 (Life 
Technologies, CA). The workflow consists of five phases: 
 
1) Amplification 
A multiplex PCR is prepared for the amplification step. Reagents and conditions of 
amplification are reported in the Table 19 and Table 20. 
43 
 
 
5x Ion AmpliseqTM HiFi Master Mix 2µl 
2X Ion AmpliSeqTM Primer Pool 1 (o 
Pool2) 
5µl 
gDNA (20ng) 1µl 
H20 Nuclease-free 2µl 
Total  volume  10µl 
 
Table 19: Reagent mix for sample used for PCR amplification. 
 
 
Temperature 
(°C) 
Time Number 
of 
cycles 
99 2' 1 
99 15'' 19 
60 4' 
10 Hold  
 
Table 20: Program of amplification 
 
2) Primers digestion 
1 µl of Fupa Reagent was added to each sample. This reagent allows the partial digestion 
of the primers and the amplicons phosphorylation. The conditions of incubation on thermal 
cycler are reported in the Table 21. 
 
Temperature 
(°C) 
Time Number of 
cycles 
99 2 ‘ 1 
99 15’’ 19 
60 4’ 
10 Hold  
 
Table 21: Program of incubation on thermal cycler. 
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3) Adapters and barcodes ligation and purification 
5 μl of the mix shown in Table 22 were added to each amplified sample. Subsequently, the 
samples were incubated on the thermal cycler according to the conditions described in 
Table 23. 
 
Switch solution 2 μl 
Ion P1 adapter 1 μl 
IonXpressTM Barcode 1 μl 
DNA Ligase 1 μl 
H20 Nuclease-free 1 μl 
Total volume 5 μl 
 
Table 22: Reagent mix prepared for the adapters and barcodes ligation. 
 
 
Temperature 
(°C) 
Time 
22 30' 
72 10' 
10 Hold 
 
Table 23: Incubations program on thermal cycler. 
 
The obtained fragments were purified through a system of magnetic beads, which bind 
(and then "select") only fragments of more than 100bp. The library of purified fragments 
was recovered after two washes with ethanol 70%. 
 
4) Libraries quantification 
The libraries obtained from the previous steps were quantified by qRT-PCR. The 
quantification was performed by use of the IonQuantification ® kit (Life Technology, CA). 
Three serial dilutions of E.coli DH10B Ion Control Library (68pM) were prepared:  6.8 pM, 
0,68 pM and 0,068 pM. This step is necessary for the calibration curve construction. The 
libraries were diluted 1:100. The qRT-PCR reagents mix was prepared as shown in Table 
24 and samples were incubated on StepOne™ Real-Time PCR System (Applied 
Biosystems) according to the conditions shown in the Table 25. 
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2X Ion TaqMan® Mastermix 10 µl 
20X Ion TaqMan®Assay 1µl 
Library (1:100) (o standard DH10B (6,8pM, 0,068pM, 
0,068pM)) 
9µl 
Total volume 10µl 
 
Table 24: Qt-pcr Reagents mix. 
 
Temperature 
(°C) 
Time Number of 
cycles 
50 2' Hold 
95 20'' Hold 
95 1' 40 
60 20'' 
 
 
Table 25: Program of incubation on StepOne™ Real-Time PCR System. 
 
5) Libraries combination 
The different libraries were combined in a single reaction tube at the same concentration 
of 8 pM.  
 
4.4.4. Template preparation 
The preparation of the templates was carried out using the Ion OneTouch™ 200 Template 
Kit v2 DL (Life Tecnology, CA).  
The emulsion PCR was prepared mixing the reagents shown in the Table 26 with mineral 
oil on the reaction filter. The reaction filter and the amplification plate were loaded on the 
Ion OneTouchTM 200 (Life Tecnology, CA). 
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Ion OneTouchTM 2X Reagent 
Mix 
500 μl 
Ion OneTouchTM Enzyme Mix 100 μl 
Ion OneTouchTM 200 Ion  
SphereTM Particles 100 μl 
Libraries 20 μl 
H20 Nuclease-free 280 μl 
Total volume 1000 μl 
 
Table 26: Emulsion mix 
 
The emulsion PCR products were recovered in two Low-Bind Tube from wich the 
supernatant solution was removed. The two pellets were combined into a unique tube with 
a volume of 1000 μl of Ion OneTouch™ Wash Solution. 
The amplification quality was checked using the Quality Control of Ion OneTouch™200 Ion 
Sphere™ Particles kit (Life Tecnology, CA). The samples were prepared in according to 
the conditions shown in the Table 27 and the Table 28. 
 
Annealing Buffer 19 µl 
Ion Probe 1µl 
Unenriched sample 2µl 
Total volume 22µl 
 
 Table 27: Quality control mix 
 
 
Temperature 
(°C) 
Time 
95 2' 
37 2' 
 
Table 28: Quality control program on thermal cycler. 
 
Before reading of samples, three washing were executed using 200 µl of Quality Control 
Buffer. Readings were made using the Qubit 2.0 fluorometer. The percentage yield of 
linked spheres to the template was obtained from the relationship between the readings 
made with the Alexa Fluor ® 488 and Alexa Fluor ® 647. A result between 10-30% 
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confirms the success of the experiment and the presence of a low amount of polyclonal 
spheres. 
The enrichment process of the emulsion PCR product was performed by the use of the Ion 
PGM™ Enrichment Beads kit on the Ion OneTouch ES machine. The 8 wells on the 
machine were filled in order with: 
1. 100 µl of emulsion PCR product 
2. 130 μl of DynaBeads®MyOneTMStreptavidin  
3. 300 μl of Ion One TouchTM Wash Solution  
4. 300 μl di Ion One TouchTM Wash Solution  
5. 300 μl di Ion One TouchTM Wash Solution  
6. Empty 
7. 300 μl Melt-Off solution (125 mM NaOH + 0,1% Tween 20  
8. Empty 
During the enrichment, the mechanical arm automatically moves the sample in the 
different wells, then releasing the enriched sample into a cuvette at the end of the 
procedure. Subsequently, 5 μl of Ion SphereTM Particles and 100 μl of Annealing Buffer 
were added to the half of the enriched sample. After centrifugation and removal of 
supernatant, 3 μl of sequencing Primers were added to the sample. 
4.4.5. Sequencing 
Two consecutive sequencing sessions were performed using in order the Chip 314 v1 
during the first session and the Chip 314 v2 during the second session. Each chip was 
loaded with sample and centrifuged to allow the polymerase and the sphere bounding 
template to settle in the micro-wells. All the sample solution was removed from chip before 
the sequencing run on the Ion Torrent PGM. 
4.4.6. Sequence Analysis  
The Ion Torrent Suite output files were analyzed using the Ion ReporterTM and Ingenuity 
online software. The Ion ReporterTM software allows to attribute the chromosomal 
locations, the protein variations, the type of inheritance,and the number of reads for each 
variant. The Ingenuity software provides some additional bioinformatics tools, such as 
SIFT, dbSNPs and Polyphen 2.0 for prediction of the variant pathogenicity. 
 
4.4.7. Validation by Sanger sequencing 
All new mutations found during the NGS analysis were checked by Sanger sequencing. 
The PCR primers were designed using the Primer3 Software (4.3.1). The primers 
sequences and the annealing temperatures for PCR amplification are reported in the Table 
29. 
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Amplicon Pimer forward Primer Rreverse Ta  
Exon 54 
(R2840G) 
TGCATGACCATTGACTCCTC TTGCCTAAAAGGGTGTTTGG 60°C  
Exon 61A 
(c.10856delA) 
CACCCACTCTGGTTCAGTCA GCTCCTTACTGTTGGCGAAT 62°C  
Exon 61B 
(R3482C)  
CCATTTGGGCAATTCAGAAG CCATTTGGGCAATTCAGAAG 58°C  
Exon 30 
(Y1136C) 
TGCATAGGGGTGACTGTGAA GGGAAAAAGAAAATACCTAACTCAAA  58°C  
Exon 65 
(R3842L) 
TTGAACACCTACTATATCCCAGATACT TTGGGGAAAGAAACAGAATCA  60°C  
 
Table 29: Primers sequences for PCR amplification 
 
The PCR were carried out in according with the conditions reported in the Table 30 and 
the Table 31. 
 
Buffer 10x 2,5 µl 
MgCl2 (2mM)  2 µl 
dNTPs 4 µl 
Primers forward and 
reverse 
0,5 µl 
Taq Gold 0,3 µl 
Total volume 25 µl 
 
Table 30: PCR mix for each sample 
 
 
Temperature (°C) Time Number of 
cycles 
95 10’ 1 
95 30’’ 35 
See Table 28 30’’ 
72 30’’ 
72 7 1 
 
Table 31: Amplification program on thermal cycler. 
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The PCR products were evaluated by electrophoresis on 2% agarose gel and compared 
with two markers of molecular weight. Subsequently, the amplified DNA was purified using 
the QIA quick PCR Purification Kit (250) (QIAGEN Inc.Valencia, CA) The concentration of 
the purified DNA fragments was assessed by electrophoresis on 2% agarose gel. 
The PCR for sequencing were performed using the BigDye Terminator v1.1 Cycle 
Sequencing kit (ABI) on the GeneAmp PCR system 9700 thermal cycler.  
PCR products were purified using the Millipore kit plate and loaded on the automatic 
sequencer 3730 DNA Analyzer, Applied Byosistem (48 capillaries). The results were 
aligned and compared with a reference sequence by using the Sequencer program (Gene 
Codes Corp, Ann Arbor, MI). 
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5. Results and Discussion 
5.1. NPHP1 deletions 
A total of 32 patients with medullar kidney cysts were submitted to the deletion analysis of 
NPHP1. In 3 patients the three homozygous deletions of the exons 5, 7 and 20 were 
identified. The Figure 26 shows the absence of three bands in the positive sample. 
 
 
 
Figure 26: 2% gel electrophoresis. Homozygous deletions in affected patient compared with two wild type 
samples. 
 
These results confirm that the homozygous deletions of NPHP1 are the most frequent 
genetic cause of NPH.  
5.2. NPHP5 mutations 
The sequence analysis of NPHP5 was performed in 5 patients with retinitis pigmentosa in 
presence of extrarenal symptoms. 
The homozygous c.1465 C>T (p.R489X) non-sense mutation in NPHP5 gene was 
detected in a patient with retinitis pigmentosa and recurrent cholangitis, confirming the 
diagnosis of Senior-Locken Syndrome (Figure 27). 
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Figure 27: electropherogram of the mutated sample in comparison with a wild type sample 
 
This mutation was previously reported  in only one Pakistani family by Otto E A et al 
(2008). The mutation c.1465 C> T (p.R489X) is a transition of a cytosine to thymine, which 
causes the replacement of the 489 arginine in a stop codon. This substitution leads to the 
production of the truncates not-functional Nephrocystin. 
5.3. REN mutations 
The REN gene mutation analysis was performed in 25 patients with renal cysts and with 
an age of onset less than 20 years. The novel heterozygous c.142G>A (p.E48K) missense 
variant was found in a patient with cystic nephropathy, hyperuricemia, hyperkalemia and 
anemia (Figure 28). 
 
 
 
Figure 28: electropherogram of the mutated sample in comparison with a wild type sample. 
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The c.142G>A is a transition of a guanine in adenine, which causes the modification of the 
the 142 glutamic acid in lysine. The mutation lies in a  conserved position (Figure 29), co-
segregated with affected family members and was absent in 50 chromosomes. 
 
 
 
Figure 29: UCSC Genome Browser conservation score. The E48 amino acid lies in a evolutionary 
conserved position.  
 
5.4. HNF1B mutations 
Molecular analysis of HNF1B was performed in 31 patients with diabetes and renal failure. 
Two large rearrangements of HNF1B gene were detected in two patients with the clinical 
features of RCAD. Identified deletions were absent in parents and relatives confirming to 
be de-novo genetic defects. 
The first whole gene heterozygous deletion of HNF1B was detected in a 17 years old 
patient with medullary cysts and renal hypoplasia (Figure 30 ).  
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Figure 30: Coffalyser.NET analysis output. 
 
A second whole gene heterozygous deletion of HNF1B was found in a 23 years old patient 
with diabetes and liver disease (Figure 31). 
 
 
 
 
Figure 31: Coffalyser.NET analysis output. 
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The heterozygous c.883 C>T (pR295C) variant of HNF1B was identified in a patient with 
renal failure and diabetes, confirming the diagnosis of MODY5 (Figure 32). 
 
 
 
Figure 32: electropherogram of the mutated sample in comparison with a wild type sample. 
 
The mutation c.883 C> T is a transition of a cytosine to thymine, which causes a 
modification of the 295 arginine in cysteine. This substitution leads to the alteration of the 
transcription factor HNF1β DNA binding domain. This mutation, not previously reported in 
Italy, was described for the first time in a french study (Bellanne-Chantelot C, 2005). 
5.5. Next Generation Sequencing output 
The NGS analysis was carried out in two subsequent experiments: the first experiment 
was performed with the aim to validate the method and the second experiment as first 
molecular diagnostics application. A 314.v1 chip (first generation) was used during the first 
run and a 314.v2 chip (second generation) was used during the second run.  
The Torrent Suite output contains a summary of the main run features (Figure 33). The 
second generation performance are best compared to the first generation chip.  
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Figure 33: Torrent Suite software output.  314v.1 chip (A) and 314v2 chip (B). The loading efficiency, the 
spheres density (ISPs), the total number of sequenced bases and the number of reads are shown in the left 
panels. The reads length is shown on the right panels. 
 
It took only 3 days of work to complete the two experiments. A total of 8 patients have 
been sequenced with each chip. The NGS method was much faster compared with the 
conventional sequencing method. A minimum of 4 weeks to many months would be 
required to sequence the same number of patients with the Sanger sequencing method. 
 
5.5.1. Annotation and filtration of variants 
A total of 40 variants have been detected during the experiments. All variants are listed in 
the Ion Reporter output (Table 30). 
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Chromosome 
position 
Type  Ref  Var   cDNA  dbSNP ID  Het Hom  MAF 1000 
Genomes 
51483961 SNP T C c.12143A>G rs9381994 3 3 0,44 
51484348 SNP G A c.11786-30C>T rs9395699 3 1 0,19 
51491884 SNP T C c.11696A>G rs4715227 3 3 0,46 
51497503 SNP C A c.11525G>T rs76572975 1 0 0,01 
51524067 DEL CT C c.10856_10856delA / 2 0 / 
51524403 SNP G A c.10521C>T rs34460237 1 0 0,07 
51524480 SNP G A c.10444C>T rs148617572 2 0 / 
51586771 SNP G A c.10156+22412C>T rs9349593 3 3 0,29 
51586772 SNP C T c.10156+22411G>A rs45451196 2 0 0,11 
51613177 SNP C T c.9237G>A rs765525 4 1 0,41 
51637561 SNP T C c.8581A>G rs150925674 1 0 <0,01 
51618170 SNP T G c.8798-19delA rs112525785 3 5 / 
51640642 SNP G C c.8518C>G rs200432861 2 0 / 
51640690 SNP G A c.8470C>T / 1 0 / 
51640751 SNP C G c.8441-32G>C rs3920621 3 2 0,42 
51695647 SNP A T c.8302+12T>A rs1571084 4 2 0,35 
51712492 SNP A T c.8107+81T>A rs9370067 2 0 0,5 
51720838 SNP T C c.7764A>G rs9349603 3 1 0,48 
51720872 SNP A G c.7734-4T>C rs7452724 3 1 0,48 
51732628 SNP G A c.7733+33C>T rs9382044 3 1 0,48 
51732807 SNP C T c.7587G>A rs12210295 3 4 0,4 
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51750563 SNP A T c.7215+102T>A rs4711985 3 1 0,47 
51776535 SNP T C c.6490+62A>G rs12196767 1 0 0,11 
51824680 INS G GT c.5895_5896insA / 1 0 / 
51875250 SNP A C c.5608T>G rs2435322 0 8 0,03 
51887643 SNP T C c.5336A>G / 1 0 / 
51889738 SNP G A c.4870C>T / 1 0 / 
51890316 SNP C T c.4292G>A / 1 0 / 
51890823 SNP G A c.3785C>T rs9296669 5 0 0,4 
51891011 SNP T C c.3629-32A>G rs2499480 4 1 0,44 
51893107 SNP T C c.3407A>G rs41273726 1 0 0,01 
51914956 SNP G A c.2278C>T rs9370096 6 0 0,41 
51917968 SNP T G c.2046A>C rs4715271 5 0 0,07 
51923409 SNP A T c.1234-10A>T rs4715272 6 0 0,11 
51924774 SNP A G c.1185T>C rs1896976 0 8 0,03 
51938242 SNP A G c.527+19T>C rs9474140 4 0 0,32 
51938417 SNP G A c.449-78C>T rs12154128 1 0 0,01 
51947237 SNP G A c.234C>T rs9474143 4 0 0,34 
51947257 SNP G A c.214C>T rs6901799 5 0 0,08 
51947999 SNP G A c.107C>T rs137852944 1 0 <0,01 
 
Table 30: Ion Reporter output. For each variant the chromosomal location, the type,  the wild type bases  in 
comparison with  bases found in samples, the position on cDNA, the rs  code if reported in dbSNP and the 
MAF frequency are reported. 
 
Among all 40 variants two frame-shift mutations (c.10856_10856delA and c.5895_5896 
INS A), a nonsense (c.8470 C> T) and 37 missense, synonymous or intronic varants were 
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identified. A further filtering step was carried out in according with the following selection 
criteria : 
 
 Insertions or deletions; 
 Non-sense variant; 
 Splicing site variant; 
 Missense; 
 Presence in HGMD; 
 MAF≤ 0,01 and absence in 1000 Genomes; 
 low detection frequency in analyzed samples; 
 Absence in dbSNP. 
 
12 filtered variants were checked using the SIFT and PolyPhen pathogenicity prediction 
software (Table 31). Among 9 missense mutations, 4 were not present in HGMD, then 
never described for the disease. The frame-shift and nonsense mutations were not 
subjected to further investigation because certainly pathogenic.  
 
CDS  Protein Exon HGMD  SIFT  PolyPhen  
c.107C>T p.T36M 3 present Damaging Probably Damaging 
c.3407A>G p.Y1136C 30 present Tolerated Possibly Damaging 
c.4292G>A p.C1431Y 32 not 
present 
Damaging Benign 
c.4870C>T p.R1624W 32 present Damaging Possibly Damaging 
c.5336A>G p.N1779S 33 not 
present 
Tolerated Probably Damaging 
c.5895_5896insA p.L1966TfsX27 36 present - - 
c.8470C>T p.Q2824X 54 not 
present 
- - 
c.8518C>G p.R2840G 54 not 
present 
Tolerated Benign 
c.8581A>G p.S2861G 55 present Tolerated Benign 
c.10856_10856delA p.K3619SfsX7 61 not 
present 
- - 
c.10444C>T p.R3482C 61 present Damaging Possibly Damaging 
c.11525G>T p.R3842L 65 not 
present 
Tolerated Probably Damaging 
 
Table 32:  The CDS location, the protein location, the exon, the presence on HGMD and the predictive 
analysis on Poliphen and Sift are reported for each mutation. 
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5.5.2. Validation 
All mutations previously identified by conventional sequencing have been detected by 
NGS (Table 33). Moreover this NGS protocol has allowed the identification of two 
additional variants not previously found by Sanger sequencing. 
 
 
Fam Samples Known  
Mutations 
NGS 
Results 
Sanger 
Results 
1 proband p.R1624W 
p.R3482C 
p.R1624W 
p.R3482C 
Np 
Np 
2 proband p.Q2824X 
p.N1779S 
p.Q2824X 
p.N1779S 
Np 
Np 
3 
 
father p.T36M p.T36M Np 
 mother p.S2861G p.S2861G 
p.R3482C 
Np 
p.R3482C 
5 proband p.C1431Y  
p.L1966fsX27 
p.C1431Y 
p.L1966Tfs 
p.Y1136C 
Np 
np 
p.Y1136C 
 
Table 33: mutations identified using the NGS protocol and the known mutations previously identified by 
Sanger Sequencing;  np = not performed 
 
The probands of the families 1 and 2 show the same mutations previously identified by 
Sanger sequencing. The NGS of the family 3 allowed to confirm the known mutations and 
also to identify an additional mutation not previously detected. This result indicates that the 
NGS method is more comprehensive than the conventional sequencing method. Also in 
the proband of the Family 4 an additional mutation was identified by NGS. In this family  
the NGS has proved to be more sensitive and useful for diagnostics application and 
genetic counseling. 
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5.5.3. Molecular diagnostics application  
The results obtained in the validation phase of this study, allowed us to proceed with a 
further molecular analysis of samples not previously characterized. A proband with 
ARPKD and his healthy parents were submitted to the NGS to evaluate the segregation of 
the mutations.  
The identified variants in the proband and his parents are reported in the Table 34. 
 
Samples 
  
NGS Results Sanger 
Results 
HGMD dbSNP SIFT  Polyphen 
Proband p.K3619SfsX7  
p.R2840G 
p.K3619SfsX7 
p.R2840G 
Not found 
Not found 
rs76572975 
rs150925674 
______ ____ 
Father p.R2840G 
p.R3842L 
p.R2840G 
p.R3842L 
Not found 
 
rs150925674 
rs200432861 
Tolerated 
Tolerated 
Benign 
Prob. 
Damaging 
Mother p.K3619SfsX7 p.K3619Sfs Not found 
 
rs76572975 _____ ______ 
 
Table 34: The CDS location, the protein location, the exon, the presence on HGMD and the predictive 
analysis on Polyphen and Sift are reported for each mutation  
 
The frame-shift p.K3619SfsX7 and the missense p.R2840G certainly causative mutations 
were identified in the proband and respectively in his mother and father. In addition, the 
father shows a second missense variant p.R3842L not transmitted to the child. The 
presence of all mutations and the absence of p.R3842L in the proband was confirmed by 
Sanger sequencing (Figure 34 ). 
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 a) b) 
 
Figure 34: a) electropherograms of the confirmed mutations by Sanger sequencing ; b) variants segregation 
in the family trio. 
p.R2840G / 
p.K3619SfsX7 
Età d’esordio 4 aa 
 
 
p.R2840G p.K3619SfsX7 
 Father 
Mother 
Proband 
62 
 
6. Conclusions 
This study provides a contribution to the knowledge of the genetic defects responsible of 
hereditary cystic kidney diseases, widening the spectrum of known mutations. This genetic 
screening allows to obtain an accurate molecular diagnosis and to better define the 
disease outcome for each patient. A careful diagnostic evaluation and an accurate genetic 
counseling are essential to ensure patient care and could lead to new therapeutic 
approaches. 
The results of this study confirm the validity of the proposed diagnostic algorithm for the 
conventional molecular screening. This genetic screening gave a molecular diagnosis in 
about 16% of our patients. The clinical phenotypes of mutation-positive patients were in 
agreement with the mutated gene. For improving the sensibility of our genetic test, it will 
be necessary to extend the screening to additional less common genes. 
The Ion Torrent PGM system used in this study for NGS screening resulted quite fast 
allowing to perform the molecular analysis of the PKHD1 gene in several patients using a 
single run. Our filtering criteria have been effective and the method resulted more sensitive 
and comprehensive than the traditional Sanger sequencing, being a powerful tool for 
molecular diagnostics and genetic counseling.  
This molecular screening for inherited cystic kidney diseases can improve the diagnostic 
capabilities and the genetic counseling for families. Furthermore, the promising 
performance of NGS suggest the possibility to introduce this technology to clinical practice, 
extending the analysis to a panel of less common genes involved in cystic diseases. 
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